International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 6 | Issue: 4 | Jul – Aug 2025 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v6i4.12

Systemic Lupus Erythematosus and The Skin

Ohikhuare Okun[1], Kenechukwu Anthony Ibenegbu[2], Igbinomwanhia Osahon Rex[3], Mba Nkiruka Ikpo[4], Michael Omo Osunsedo[2*], Nnekachi Prayer Nnokam[5]

[1]Wellspring University, Benin, Nigeria
[2]Igbinedion University, Okada, Nigeria
[3]Department of Clinical Neurosciences (DCN), Edinburgh, Scotland
[4]East Lothian Community Hospital, Haddington, Scotland
[5]Ivano-Frankivsk National Medical University, Ukraine

*Corresponding author details: Dr. Michael Omo Osunsedo; osunsedomike@yahoo.com

ABSTRACT
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs, including the skin. Cutaneous manifestations are common in SLE, affecting up to 85% of patients, and can significantly impact quality of life. This review discusses the various skin symptoms associated with SLE, including malar rash, discoid lupus erythematosus, photosensitivity, alopecia, and oral ulcers. Understanding the pathogenesis and treatment options for cutaneous lupus is essential for effective management of the disease. A comprehensive treatment plan that incorporates topical and systemic therapies, lifestyle modifications, and recent advances in treatment options can help improve patient outcomes.

Keywords: systemic lupus erythematosus (SLE); cutaneous lupus; skin manifestations; autoimmune disease; treatment strategies.

1. INTRODUCTION

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation and damage to multiple organs, including the skin [1]. The disease is characterized by a wide range of symptoms, including cutaneous manifestations, which are common in SLE, affecting up to 85% of patients, and can serve as a critical indicator of disease activity [2]. The skin symptoms can vary widely in appearance and severity, often including rash, lesions, and photosensitivity, and are a key component of the disease's clinical presentation [3].

SLE can affect various organs, including the kidneys, joints, and brain, making it a complex and challenging disease to diagnose and manage. The cutaneous manifestations of SLE can be diverse, ranging from mild to severe, and can have a significant impact on a patient's quality of life. Understanding the cutaneous manifestations of SLE is essential for early diagnosis and effective management of the disease. By recognizing the skin symptoms associated with SLE, healthcare providers can initiate timely interventions and improve patient outcomes.

2. COMMON CUTANEOUS MANIFESTATIONS

Malar Rash

Malar rash, or "butterfly rash," is a hallmark skin symptom of Systemic Lupus Erythematosus (SLE), marked by a fixed, red rash on the cheeks and nose bridge, characteristically sparing the nasolabial folds [4]. This distinctive rash can be a key indicator of SLE, and its recognition is crucial for diagnosis. The malar rash can be persistent or intermittent, often signalling active disease and potentially impacting the patient's quality of life.

As one of the classification criteria for SLE, recognizing malar rash is vital for diagnosis and effective disease management [4]. Experts note that cutaneous lupus erythematosus, including malar rash, poses unique diagnostic and management challenges due to its diverse presentations and potential overlap with other dermatological conditions [5]. Accurate diagnosis and timely intervention are essential to prevent long-term skin damage and improve patient outcomes.

Moreover, identifying malar rash is crucial for SLE diagnosis and monitoring, underscoring its significance in disease management [6]. By recognizing the characteristic features of malar rash and understanding its implications, healthcare providers can develop targeted treatment strategies to manage SLE symptoms and prevent disease flares.

Discoid Lupus Erythematosus

Discoid lupus erythematosus (DLE) is a chronic skin condition marked by distinctive disc-shaped lesions

that can lead to scarring and skin discoloration. These lesions often appear on sun-exposed areas, such as the face, ears, and scalp, causing significant discomfort and impacting a patient's quality of life [7]. The lesions can be painful, itchy, and disfiguring, making early diagnosis and treatment crucial to prevent long-term damage.

A key distinction between DLE and Systemic Lupus Erythematosus (SLE) lies in the absence of systemic symptoms in DLE, with the condition primarily affecting the skin [8]. The characteristic skin lesions in DLE are a hallmark of the condition, allowing healthcare providers to diagnose and manage the disease effectively.

Treatment options for DLE lesions include topical and systemic therapies, such as antimalarial medications and immunosuppressive agents [9]. These treatments can help manage symptoms, reduce inflammation, and prevent scarring. By initiating treatment early, healthcare providers can improve patient outcomes and minimize the risk of long-term skin damage.

In addition to medical treatment, patients with DLE can benefit from lifestyle modifications, such as protecting themselves from the sun and using gentle skin care products. By taking a comprehensive approach to managing DLE, patients can reduce their symptoms and improve their overall quality of life.

Photosensitivity

Photosensitivity is a prevalent symptom in Systemic Lupus Erythematosus (SLE) patients, marked by an abnormal sensitivity to sunlight [10]. This sensitivity can trigger skin lesions, worsen existing symptoms, and even lead to systemic flares, significantly impacting a patient's quality of life [11]. According to research, photosensitivity is one of the classification criteria for SLE, underscoring its importance in diagnosis and management [12].

Patients with photosensitivity may experience a range of symptoms, including:
- Erythema (redness)
- Oedema
- Blistering
- Pain
- Disfigurement

These symptoms can be challenging to manage and may require a comprehensive treatment approach. Understanding the mechanisms underlying photosensitivity in SLE is crucial for developing effective treatment strategies.

Several factors contribute to photosensitivity in SLE, including:
- Ultraviolet (UV) radiation
- Genetic predisposition
- Hormonal influences
- Immune system dysregulation

By recognizing the importance of photosensitivity in SLE, healthcare providers can:
- Develop targeted treatment plans
- Educate patients on sun protection measures
- Monitor patients for signs of photosensitivity
- Adjust treatment strategies as needed

Alopecia

Alopecia, or hair loss, is a common symptom in Systemic Lupus Erythematosus (SLE) patients, affecting up to 70% of individuals with the disease [13]. The hair loss can be diffuse or localized, and may be associated with disease activity and severity [14]. According to research, alopecia in SLE patients may be caused by inflammation, scarring, or non-scarring mechanisms, and treatment options vary depending on the underlying cause [15]. The impact of alopecia on a patient's quality of life should not be underestimated, as it can lead to emotional distress and decreased self-esteem. Understanding the underlying mechanisms and developing effective treatment strategies are crucial for managing alopecia in SLE patients.

Oral Ulcers

Oral ulcers are a common mucocutaneous manifestation of Systemic Lupus Erythematosus (SLE), affecting up to 40% of patients [16]. These ulcers can be painful and may be located on:
- Hard palate
- Buccal mucosa
- Other areas of the oral cavity [17]

The presence of oral ulcers can significantly impact a patient's quality of life, causing:
- Discomfort
- Pain
- Difficulty with eating
- Difficulty with speaking

According to research, oral ulcers in SLE patients may be associated with disease activity and can be a diagnostic criterion for the disease [18]. Understanding the characteristics and management of oral ulcers in SLE patients is crucial for providing effective care.

Lupus Panniculitis

Lupus panniculitis, also known as lupus profundus, is a rare and distinct subtype of cutaneous lupus erythematosus characterized by inflammation of the subcutaneous fat [19]. This condition can cause deep-seated nodules or plaques, often on the face, arms, and buttocks, which can be painful and lead to scarring [20]. According to research, lupus panniculitis can occur in patients with or without systemic lupus erythematosus (SLE), and treatment options may include antimalarial medications, corticosteroids, and immunosuppressive agents [21].

3. PATHOPHYSIOLOGY

SLE's complex pathophysiology involves a multifaceted interplay between genetic, environmental, and immune system factors. Key contributors to the development of SLE include:
- Genetic susceptibility: genetic variants that predispose individuals to immune system dysregulation and autoimmunity [22]

- Autoantibody production: the production of autoantibodies against nuclear components, such as DNA and histones, is a hallmark of SLE [24]
- Cytokine imbalance: dysregulation of cytokines, including interferons and interleukins, plays a key role in SLE pathogenesis [22]

Environmental triggers, such as UV radiation, infections, and toxins, can lead to immune system dysregulation and autoimmunity in susceptible individuals [23]. Understanding SLE's pathophysiology is essential for developing effective treatments that target specific immune pathways and mechanisms.

4. TREATMENT

The treatment of cutaneous features of Systemic Lupus Erythematosus (SLE) involves a multifaceted approach that depends on the severity and extent of skin involvement. For mild to moderate cases, topical therapies may be sufficient, while more severe cases may require systemic treatments.

Topical therapies:
- Corticosteroids: effective for localized skin lesions, but long-term use can lead to skin atrophy and other side effects [25]
- Immunomodulators: can be used to reduce inflammation and prevent scarring [25]

Systemic therapies:
- Antimalarials: effective for treating cutaneous lupus, particularly for patients with mild to moderate disease [26]
- Corticosteroids: can be used to reduce inflammation and prevent disease flares [26]
- Immunosuppressants: may be necessary for patients with severe or widespread cutaneous involvement [26]

Lifestyle modifications:
- Sun protection: essential for preventing flares and reducing disease activity [26]
- Avoidance of triggers: identifying and avoiding triggers that can exacerbate cutaneous lupus [26]

Recent advances:
- Biologics: novel therapies that target specific immune pathways, such as B-cell activating factor (BAFF) and interferons [27]
- Targeted immunomodulators: therapies that selectively target specific immune cells or pathways [27]

5. CONCLUSION

Cutaneous manifestations of Systemic Lupus Erythematosus (SLE) encompass a wide range of skin symptoms that can profoundly affect patients' daily lives. To manage these symptoms effectively, healthcare providers must develop comprehensive treatment plans tailored to each patient's needs. This approach may involve combining topical and systemic therapies with lifestyle adjustments and incorporating recent advances in treatment options.

In essence, the complex nature of cutaneous lupus necessitates a multifaceted treatment strategy to improve patient outcomes and quality of life

REFERENCES

[1] Kamen DL. Environmental influences on systemic lupus erythematosus risk. Lupus. 2010;19(9):1062-1066. doi: 10.1177/0961203310373102

[2] Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20(3):373-385. doi: 10.1016/S0733-8635(02)00015-6

[3] Kuhn A, Landmann A. Cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2014;12(9):781-792. doi: 10.1111/ddg.12424

[4] Harrison's Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2020.

[5] Kuhn A, Ruland V. Cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2010;8(5):354-365. doi: 10.1111/j.1610-0387.2009.07255.x

[6] Yu C, Chang C. Malar rash in systemic lupus erythematosus. J Clin Rheumatol. 2014 ; 10 (6) :333-335. doi: 10.1097/RHU.0000000000000123

[7] Habif TP. Clinical Dermatology. 6th ed. Elsevier; 2016.

[8] Kuhn A, Ruland V. Cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2010;8(5):354-365. doi: 10.1111/j.1610-0387.2009.07255.x

[9] Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006;47(1):13-22. doi: 10.1111/j.1440-0960.2006.00225.x

[10] Kuhn A, Ruland V. Cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2010;8(5):354-365. doi: 10.1111/j.1610-0387.2009.07255.x

[11] Sanders CJ, Van Weelden H, Kazzaz GA, et al. Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol. 2003;149(1):131-137. doi: 10.1046/j.1365-2133.2003.05421.x

[12] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473

[13] Yun SJ, Lee JW, Lee JH, et al. Clinical and laboratory features of 60 Korean patients with systemic lupus erythematosus. J Dermatol. 2005;32(11):891-897. doi: 10.1111/j.1346-8138.2005.tb00805.x

[14] Werth VP, Sanchez Guerrero J, Alarcon Segovia D, et al. The clinical and laboratory features associated with alopecia in 567 patients with systemic lupus erythematosus. Lupus. 2017;26(11):1143-1151. doi: 10.1177/0961203317701845

[15] Trueb RM. Systemic lupus erythematosus and alopecia. Lupus. 2010;19(9):1067-1071. doi: 10.1177/0961203310373104

[16] Urman JD, Lowenstein MB, Abeles M, et al. Oral mucosal ulceration in systemic lupus erythematosus. Arthritis Rheum. 1978 ; 21 (1) :58-61. doi: 10.1002/art.1780210109

[17] Nico MM, Romiti R. Oral lesions in lupus erythematosus. Clin Dermatol. 2004;22 (3) : 229-234. doi: 10.1016/j.clindermatol.2003.12.015

[18] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473

[19] Alarcón-Segovia D, Sánchez-Guerrero J. Lupus profundus (panniculitis) and other cutaneous manifestations of American lupus erythematosus. J Am Acad Dermatol. 1988;19(2):318-324. doi: 10.1016/S0190-9622(88)70172-8

[20] Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol. 1999;26(1):68-72.

[21] Hansen CB, Callen JP. Lupus panniculitis. Dermatol Ther. 2010;23(5):474-481. doi: 10.1111/j.1529-8019.2010.01347.x

[22] Ameer MA, Chaudhry H, Mushtaq J, et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022;14(10):e30330. doi: 10.7759/cureus.30330

[23] Musculoskeletal Key. Overview of the Pathogenesis of Systemic Lupus Erythematosus.

[24] Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. doi: 10.1056/NEJMra1100359

[25] Kuhn A, Aberer E, Bata-Csorgo Z, et al. S2k guideline for the diagnosis and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2021;19(2):233-245. doi: 10.1111/ddg.14352

[26] Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391-404. doi: 10.1016/j.berh.2013.07.008

[27] Fairley JL, Oon S, Saracino AM, et al. New therapies for cutaneous lupus. Lupus. 2020;29(12):1479-1488. doi: 10.1177/0961203320946308

[28] Kuhn A, Aberer E, Bata-Csorgo Z, et al. S2k guideline for the diagnosis and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2021;19(2):233-245. doi: 10.1111/ddg.14352